U.S. License Holder:
Centocor Inc. (Janssen Biotech, Inc.)
Date of License:
ReoPro (abciximab) is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications:
in patients undergoing percutaneous coronary intervention;
in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours.
U.S. Patent LitigationsPACER
U.S. Patent Nos.
4,816,567 (Recombinant Immunoglobulin Preparations) 6,171,586 (Antibody Formulation) 6,331,415 (Methods of Producing Immunoglobulins, Vectors and Transformed Host Cells for Use Therein) 6,333,398 (Protein Purification) 6,417,335 (Protein Purification) 6,870,034 (Protein Purification)
Centocor Ortho Biotech, Inc.
City of Hope; Genentech, Inc.